Introduction
In hematopoietic SCT (HSCT), high-dose BU has been widely used, mostly in combination with CY. 1 To overcome the disadvantage of oral BU including gastrointestinal absorption, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] i.v. BU was recently introduced into clinical use. [17] [18] [19] [20] The initial experience with i.v. BU showed satisfactory dose assurance with reliable predictability of pharmacokinetics without dose adjustment. 19 Hence, it is very probable that its use reduces the incidence of various risks at transplantation such as hepatic venoocclusive disease (VOD), as shown by Kashyap et al. 21 Nevertheless, drug profiles of i.v. BU preparation have not been fully evaluated in different races, who may have different pharmacokinetics. As part of our pivotal study in Japan, we conducted a phase II study with pharmacokinetic analysis of a combined i.v. BU and CY (BU/CY) regimen administered before allogeneic or autologous HSCT. A population pharmacokinetic analysis suggested that i.v. BU pharmacokinetics show high inter-and intrapatient consistency. 22 This study with the same population further focused on complete pharmacokinetic profiles with additional clinical and safety data.
Patients and methods

Eligibility criteria
Patients with acute leukemia, CML, MDS or malignant lymphoma were eligible for this study. Patients aged 5-55 years with a Lansky Performance Status 470 (over 5 and less than 16 years of age) or an Eastern Cooperative Oncology Group Performance Status p2 (16-55 years of age) who were expected to survive beyond 100 days after HSCT were eligible. The eligibility criteria also included serum creatinine less than twice the upper normal limit, as well as serum total bilirubin less than 1.5 times, and aspartate aminotransferase, alanine aminotransferase and gamma-glutamyltranspeptidase less than three times the upper normal limit. Left ventricular ejection fraction X50% or arterial blood oxygen saturation X94%, and in adult patients a carbon monoxide lung diffusing capacity X60%, were required. Patients with arrhythmia, hypertension or diabetes mellitus that was difficult to control despite medication, severe cardiopulmonary or renal disease, chronic active hepatitis, liver cirrhosis, acute hepatitis, ascites more than 1 l, central nervous system disorders, active infection; positive hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody or human immunodeficiency virus antigen/antibody; or prior HSCTs were all excluded. Patients were also required to have either BM available from an HLA-matched related or unrelated donor or G-CSF-mobilized PBSCs available from an HLA-matched related donor without T-cell depletion. The study was conducted in conformity with ICH-GCP and the Declaration of Helsinki. The protocol and informed consent forms were approved by each institution's Research Ethics Committee. All patients gave written informed consent prior to their participation in the study.
Conditioning regimen
The i.v. BU (KRN246; Kirin Pharma Co. Ltd., Tokyo, Japan) was given at 0.8 mg/kg through a central venous catheter for 2 h every 6 h at a total of 16 doses for 4 days on days À7 to À4. CY 60 mg/kg was administered through a central venous catheter for 3 h at a total of two doses for 2 days on days À3 and À2. After a rest on day À1, BM or G-CSF-mobilized PBSC without T-cell depletion was infused on day 0. A fixed-dose regimen for BU was calculated based on either the ideal body weight or actual body weight, whichever was less, for adults (18-55 years of age) and the actual body weight for children (over 5 and less than 18 years of age).
Supportive care
For seizure prophylaxis, phenytoin was administered at 5-10 mg/kg/day (upper limit of 300 mg/kg/day) in 2-3 divided doses starting from 2 days before initiation (day À9) to 48 h after completion of BU administration (day À2). G-CSF was administered on day 1 or 5 until engraftment. For patients undergoing allogeneic HSCT, GVHD prophylaxis consisted of CYA (3 mg/kg/day by continuous i.v. infusion from day À1 in related and 3-5 mg/ kg/day in unrelated transplantation) and short-term methotrexate, that is, 10 mg/m 2 on day 1 and 7 mg/m 2 on days 3 and 6 in related pairs or 10 mg/m 2 on day 1 and 7 mg/m 2 on days 3, 6 and 11 in unrelated pairs. Mesna was administered at a dose equivalent to 120% of CY on days À3 and À2. Other supportive treatments including antiemetic administration, antibiotic treatment, transfusion support, GVHD treatment and VOD treatment were given according to the standards of each hospital.
Evaluation of clinical data
The efficacy variables were myeloablation, engraftment, relapse, overall survival (OS) and disease-free survival (DFS). The safety variables were non-relapse mortality and adverse events included convulsive seizure, VOD, acute GVHD and other organ toxicities. Engraftment was defined as an absolute neutrophil count of 0.5 Â 10 9 /l for three consecutive days. Engraftment failure was defined as the failure to reach an absolute neutrophil count of 0.5 Â 10 9 /l by day 28 after transplantation. OS was measured as the time from the day of transplantation until death from any cause, and DFS as the time from the day of transplantation until disease relapse or death from any cause. Relapse, OS and DFS were calculated using the Kaplan-Meier method. 23 non-relapse mortality was defined as any death without progression of the underlying disease. Patients were monitored daily for adverse events, hematology and transplant-related complications. After discharge, patients were followed weekly for adverse events and transplant-related complications, and monitored weekly for hematologic and biochemical data through 100 days after transplantation. The appearance of VOD by day 30 was evaluated based on any two of the major criteria as established by McDonald et al. 24 and Jones et al. 25 GVHD was graded according to the consensus criteria. 26, 27 Kirin Pharma Co. Ltd. provided financial support for the medical costs associated with the conditioning regimen, including i.v. BU for enrolled patients, monitored source data and entered these data in a database. Statistical analysis was performed using SAS software (version 8.02; SAS Institute, Cary, NC, USA).
PK sampling and analysis
The objective of this study was to describe the PK characteristics of i.v. BU, with parameters including BU concentrations for the first and ninth administrations and the accumulation of i.v. BU. Plasma samples were collected from all patients at designated times, in conjunction with the first and ninth doses as follows: immediately before drug infusion and at 15, 30 and 45 min after the start of infusion, at 5 min before the end of infusion and at 15, 30, 60, 120, 180 and 240 min after completion of infusion. In addition, one sample was taken immediately before the 13th infusion and 5 min before its completion. The plasma was assayed using a gas chromatographic-mass spectrometric detection method. 10 Plasma concentrations for first and ninth dose in individual subjects were analyzed by the non-compartmental method using WinNonlin (version 3.3; Pharsight Corp., Mountain View, CA, USA). The maximum plasma concentration (C max ) and the time to reach maximum plasma drug concentration (t max ) were observed values. The terminal half-life (t 1/2 ) was calculated as ln2/k el , where k el was the elimination rate constant, determined by log-linear regression of the terminal phase data points. The area under the plasma concentration-time curve from time 0 to infinity (AUC inf ) for the first dose was calculated as AUC 0Àt þ C t /k el , where AUC 0Àt was the AUC from time 0 to the last detectable time, calculated using linear trapezoidal rule, and C t was the plasma concentration at the last detectable time. AUC at steady state (AUC ss ) for the ninth dose was calculated by the linear trapezoidal rule. Clearance (CL) was calculated as dose/AUC. Volume of distribution (V z ) was calculated as CL/k el . CL and V z were normalized to actual individual body weight (CL/ABW and V z /ABW) on the day of dosing. Summary statistics were obtained for C max , t max , t 1/2 , AUC, CL/ABW and V z /ABW at the first and ninth dose. The AUC at dose 1 (AUC inf ) and dose 9 (AUC ss ) and the trough concentration (C p,trough ) and peak concentration (C p,peak ) at doses 9 and 13 were calculated and compared by preparing each plot.
Results
Patient characteristics
Thirty Japanese patients were registered in this prospective trial between July 2002 and October 2003. The disease characteristics and status at transplantation are given in Table 1 . The median age of the patients was 30 years (range, 7-53 years). The median body mass index (BMI) was 22.65 (14.4-29.1), and the mean BMI was 22.32±3.47. There were no patients with moderate or severe obesity (BMI o30). The diseases were AML in 13 patients (43%), ALL or CML in chronic phase in five patients each (17%), non-Hodgkin lymphoma (NHL) in four patients (13%) and MDS in three patients (10%). In total, 11 of the 12 patients with AML were in CR. Four of the five patients with ALL were in CR. Three patients with MDS included refractory anemia, refractory anemia with excess blasts and refractory anemia with excess blasts in transformation. Four patients with NHL included diffuse large B-cell lymphoma in CR (n ¼ 2), primary refractory peripheral T-cell lymphoma (n ¼ 1) or suspected extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in CR (n ¼ 1). One patient with AML who was in remission at registration was subsequently withdrawn from protocol treatment due to onset of cardiac myopathy on day À3, and CY was changed to fludarabine. Owing to an additional protocol violation, this patient was excluded from the objective group in the analysis.
Engraftment
Twenty-eight patients (97%) achieved engraftment at a median of 14 days (range, 9-20 days) and 11 days after allogeneic and autologous HSCT, respectively (Table 2) . One patient who received unrelated BMT for CML had graft failure. No secondary engraftment failure was observed.
Toxicity and complications
All adverse events were those that are commonly observed in HSCT and no characteristic events related to i.v. BU were observed. None of the patients had to interrupt i.v. BU treatment because of adverse events. The number of observed adverse events was 714 in 27 patients who received allogeneic HSCT and 19 in two patients who received autologous HSCT. The most frequent adverse events in the 27 allogeneic HSCT patients were vomiting and nausea in 20 patients each (74%), anorexia in 19 patients (70%), stomatitis and diarrhea in 18 patients each (67%) and headache in 17 patients (63%; Table 2 ). Both of the autologous HSCT patients showed stomatitis, vomiting, catheter-related infection, anorexia and dysgeusia. No seizures were observed, and with regard to other neuropsychological profiles, seven patients experienced mild dysgeusia, one moderate systemic burning sensation, one severe tremor, one severe mood change and one severe insomnia in an allogeneic setting. With regard to cardiovascular profiles, one patient experienced mild cardiac failure and the other developed moderate cardiomyopathy due to CY in the allogeneic setting, as described above. This patient had completed i.v. BU administration for 4 days and CY once. When the patient complained of chest discomfort, the heart rate was 101 beats/min, and her electrocardiography showed ST depressions in leads II, III, aVF and V 1 -V 6 1 h after the completion of the first dose of CY, which made suspected diagnosis of CY-induced cardiomyopathy. The signs and symptoms subsided shortly, and the second dose of CY on day À2 was substituted by fludarabine with no subsequent complications.
One patient who received allogeneic HSCT was diagnosed with mild VOD on day 1 based on two diagnostic criteria, 24, 25 which resolved on day 3. In another patient, elevated total bilirubin and body weight gain were found on days 60-69, and this was not confirmed to be VOD based on these criteria. Opportunistic infection occurred in 16 of 27 patients (59%), with a median onset of day 113 (range, 7-399). Pulmonary complications occurred in 7 of 27 patients (26%), with a median onset of day 149 (range, 65-335).
GVHD
Acute GVHD occurred in 13 of the 27 patients (48%) who received allogeneic HSCT; four (15%) had grade I, five (19%) grade II and two each (7%) grades III or IV (Table 2) . Acute GVHD was documented in 7 of the 19 patients (37%) who received related transplantation (six had grades II-IV), and in six of the eight patients (75%) who received unrelated transplantation (three patients had grades II-IV). Acute GVHD occurred with a median onset of day 45 (range, 7-98). Chronic GVHD occurred in 16 of 27 patients (59%) with a median onset of day 133 (range, 39-239).
Causes of death
Four patients (15%) died of non-relapse causes (Table 2) . One patient who received allogeneic HSCT died of multiorgan failure due to aggravated GVHD on day 69. Three patients who received allogeneic HSCT died of chronic GVHD on day 223, hepatic failure due to unknown reasons on day 266 (with extensive chronic GVHD and methicillinresistant staphylococcus aureus (MRSA) pneumonia) and pneumonia due to adenovirus and cytomegalovirus on day 124. Four patients (15%) died of relapse.
Relapse and survival
Relapse occurred in 9 of the 23 evaluable allogeneic HSCT patients with leukemia and lymphoma (39%). None of the 23 evaluable patients had central nervous system relapse. The relapse rates at days 100 and 365 were 18% (95% confidence interval (CI), 0-38%) and 26% (95% CI, 8-45%), respectively ( Figure 1) . The median day of relapse was day 202 (range, 46-476).
OS at days 100 and 365 in allogeneic HSCT was 96% (95% CI, 88-100%) and 78% (95% CI, 62-94%), respectively, with the median follow-up of 413 days (range, 69-537 days) (Figure 2) . The median day of death in eight allogeneic HSCT patients was day 208 (range, 69-467). DFS at days 100 and 365 in allogeneic HSCT was 81% (95% CI, 63-99%) and 63% (95% CI, 45-81%), respectively (Figure 2 ). The two autologous HSCT patients were alive disease-free at day 365.
PK analysis
Intensive PK sampling was assessed at doses 1 and 9 of i.v. BU, and peak and trough levels were obtained at dose 13. Although these analyses were completed in all 30 patients, Table 2 Regimen-related toxicity, engraftment, GVHD and death Graft failure 1 (4) 0 (0) data from one patient were excluded from the objective analysis group as noted above. All PK parameters for dose 1 were obtained from 29 patients. For dose 9, all PK parameters except for C max and t max were obtained from 28 patients because the last sample for one patient was collected after initiation of the next dose ( Figure 3) . The documented plasma concentration of i.v. BU increased over the 2-h period of infusion, with C max observed in the last 5 min, and this was followed by a rapid decrease. The profile of trough and peak levels was essentially the same between doses 9 and 13. The resulting parameters are listed in Table 3 . The mean AUC for doses 1 and 9 was 1171 mmol min/l (coefficient of variation (CV) ¼ 19%) and 1242 mmol min/l (CV ¼ 17%), and the mean C max was 994 ng/ml (CV ¼ 12%) and 1311 ng/ ml (CV ¼ 15%), respectively. The mean CL/ABW was 2.66 ml/min/kg (CV ¼ 17%) and 2.46 ml/min/kg (CV ¼ 15%), respectively. V z /ABW was 0.60 l/kg (CV ¼ 9%) and 0.60 l/kg (CV ¼ 11%), respectively. The AUC of the initial dose was below 1500 mmol min/l in 27 patients (90%), and this was within the range of 900-1350 mmol min/l in 21 of the 29 patients (72%).
The AUC for doses 1 and 9 are compared in Figure 4 , which supports both intra-and interpatient predictability and consistency. In the patient who developed VOD, the AUC for doses 1 and 9 was 1102 and 1181 mmol min/l, respectively, whereas for the remaining patients without VOD, it was 1173 mmol min/l (CV ¼ 19%) and 1244 mmol min/l (CV ¼ 17%).
Pediatric patients
A 7-year-old girl with AML in first remission received allo-BMT from a matched unrelated donor. Her body weight and BMI were 17.8 kg and 14.4, respectively. Her AUC was 963.9 mmol min/l. Her regimen-related toxicities were grade 3 vomiting and grade 2 acute hemorrhagic gastritis and hypoalbuminemia. She is alive without graft failure or relapse.
A 13-year-old boy with CML in first chronic phase received allo-BMT from a matched unrelated donor. His body weight and BMI were 46.7 kg and 18.8, respectively. His AUC was 932.6 mmol min/l. His regimen-related toxicities were grade 4 anorexia and grade 2 fatigue and vomiting. He did not achieve engraftment by day 28, and he soon received a second allo-BMT from a mismatched related donor. He is alive without graft failure or relapse after the second transplant.
A 17-year-old woman with AML in first relapse received allo-BMT from a matched unrelated donor. Her body weight and BMI were 43.2 kg and 17.3, respectively. Her AUC was 902.7 mmol min/l. Her regimen-related toxicities were grade 4 thrombocytopenia, grade 3 febrile neutropenia and grade 2 nausea, vomiting and stomatitis. She died of disease progression on day 193.
Discussion
It has been reported that a high steady-state concentration of BU causes toxicities including VOD, 5-10 whereas a low steady-state concentration leads to graft rejection [10] [11] [12] [13] [14] [15] or relapse/progression of the disease. 11 Targeted dose adjustment of BU to maintain the overall systemic exposure within a proper range may reduce these risks. [4] [5] [6] [7] 14, 15 Although it has been reported that there are ethnic differences in PK for a wide range of drugs, 28 this has not been seriously examined with i.v. BU. Therefore, we conducted this drug bioavailability study in a Japanese population. The data obtained were compared with those published mostly overseas. In this study, all observed treatment-related toxicities were as expected, with a low incidence of severe complications. One patient was clinically diagnosed with VOD. This patient showed body weight gain, liver enlargement and right upper abdominal pain, but had no jaundice. As his body weight returned to the baseline within 2 days, this could have been due to overhydration. One patient who developed graft failure had CML and underwent unrelated BMT following interferon therapy, all of which are well-known risks of graft failure. 10, 29 The incidence of relapse and the survival rate in this study were similar to those in previous studies. 11, 19 In studies with an oral preparation of BU, it was unclear whether plasma levels of BU correlate with severe regimen-related toxicities. 4, [6] [7] [8] 11 In the pivotal study for US approval of i.v. BU, plasma levels of BU exceeded 1500 mmol min/l in two of the five patients who developed VOD, 19 whereas in our study there was no case of VOD in three patients who had a level over 1500 mmol min/l. This may suggest an ethnic difference in the PK of BU. On the other hand, a population pharmacokinetic analysis of i.v. BU is rare. 30 Our earlier small-scale study revealed high inter-and intrapatient consistency for i.v. BU pharmacokinetics. 22 However, the value of therapeutic drug monitoring remains crucial. Our study demonstrated no essential difference in PK analysis from earlier published Western data, 19 and this supports the notion that racial factors may not seriously influence the bioactivity of i.v. BU.
